Charles River has acquired Cellero to complement recent acquisition of HemaCare by enhancing the supply of critical biomaterials
Charles River has announced the acquisition of Cellero (formerly Key Biologics and Astarte Biologics), a provider of cellular products for cell therapy developers and manufacturers worldwide.
Cellero will complement Charles River's recent acquisition of HemaCare by enhancing the supply of critical biomaterials, including a wide range of human-derived primary cell types to support the discovery, development, and manufacture of cell therapies.
The combination of Cellero with HemaCare will enhance Charles River's unique, comprehensive solutions for the high-growth cell therapy market, strengthening its ability to help accelerate clients' critical programs from basic research and proof-of-concept to regulatory approval and commercialization. It will also expand Charles River's provision of high-quality, human-derived biomaterials and related services with Cellero's unique product portfolio and donor sites in both the eastern and western United States.